CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Ocuphire Pharma, Inc. - OCUP CFD

    3.31
    3.78%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 3.44
    Open* 3.45
    1-Year Change* 69.95%
    Day's Range* 3.1 - 3.45
    52 wk Range 1.90-6.60
    Average Volume (10 days) 159.29K
    Average Volume (3 months) 2.88M
    Market Cap 83.82M
    P/E Ratio 5.61
    Shares Outstanding 21.01M
    Revenue 45.27M
    EPS 0.71
    Dividend (Yield %) N/A
    Beta 0.32
    Next Earnings Date Nov 2, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 29, 2023 3.31 -0.15 -4.34% 3.46 3.51 3.05
    Sep 28, 2023 3.44 -0.37 -9.71% 3.81 3.81 3.38
    Sep 27, 2023 3.73 -0.26 -6.52% 3.99 4.10 3.58
    Sep 26, 2023 3.99 0.16 4.18% 3.83 4.38 3.83
    Sep 25, 2023 3.88 0.02 0.52% 3.86 3.89 3.80
    Sep 22, 2023 3.83 -0.04 -1.03% 3.87 3.94 3.80
    Sep 21, 2023 3.86 -0.03 -0.77% 3.89 3.92 3.82
    Sep 20, 2023 3.94 -0.01 -0.25% 3.95 3.96 3.91
    Sep 19, 2023 3.99 0.05 1.27% 3.94 4.01 3.90
    Sep 18, 2023 3.94 -0.04 -1.01% 3.98 4.02 3.91
    Sep 15, 2023 3.97 0.06 1.53% 3.91 4.05 3.91
    Sep 14, 2023 3.99 0.06 1.53% 3.93 4.02 3.79
    Sep 13, 2023 3.87 -0.16 -3.97% 4.03 4.07 3.85
    Sep 12, 2023 4.05 0.07 1.76% 3.98 4.07 3.97
    Sep 11, 2023 4.00 0.01 0.25% 3.99 4.01 3.89
    Sep 8, 2023 3.97 0.03 0.76% 3.94 4.07 3.93
    Sep 7, 2023 3.95 0.19 5.05% 3.76 3.97 3.76
    Sep 6, 2023 3.79 0.00 0.00% 3.79 3.84 3.74
    Sep 5, 2023 3.82 -0.11 -2.80% 3.93 3.96 3.78
    Sep 1, 2023 3.89 0.01 0.26% 3.88 3.96 3.86

    Ocuphire Pharma, Inc. Events

    Time (UTC) Country Event
    Thursday, November 2, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Ocuphire Pharma Inc Earnings Release
    Q3 2023 Ocuphire Pharma Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 39.85 0.589 0 0 0
    Revenue 39.85 0.589 0 0
    Total Operating Expense 21.624 23.29 16.292 11.215 20.5377
    Selling/General/Admin. Expenses, Total 7.269 8.121 2.818 5.72863 7.42862
    Research & Development 14.355 15.173 6.648 5.47678 13.1091
    Unusual Expense (Income) -0.004 6.826 0.00959
    Operating Income 18.226 -22.701 -16.292 -11.215 -20.5377
    Interest Income (Expense), Net Non-Operating -0.009 -33.831 -8.333 2.57957 5.80039
    Net Income Before Taxes 18.203 -56.693 -24.62 -8.63543 -14.3685
    Net Income After Taxes 17.888 -56.693 -24.62 -8.63543 -14.3685
    Net Income Before Extra. Items 17.888 -56.693 -24.62 -8.63543 -14.3685
    Net Income 17.888 -56.693 -24.62 -8.63543 -14.3685
    Income Available to Common Excl. Extra. Items 17.888 -56.693 -24.62 -8.63543 -14.3685
    Income Available to Common Incl. Extra. Items 17.888 -56.693 -24.62 -8.63543 -14.3685
    Diluted Net Income 17.888 -56.693 -24.62 -8.63543 -14.3685
    Diluted Weighted Average Shares 20.5972 14.8527 4.66111 0.99004 0.68574
    Diluted EPS Excluding Extraordinary Items 0.86847 -3.817 -5.282 -8.7223 -20.9534
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS 0.86847 -3.81727 -3.81755 -8.71261 -20.9534
    Other, Net -0.014 -0.161 0.005 0 0.36875
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 3.674 1.749 39.85 0 0
    Total Operating Expense 9.063 7.88 5.64 4.538 4.938
    Selling/General/Admin. Expenses, Total 4.34 2.285 2.054 1.703 1.776
    Research & Development 4.723 5.595 3.586 2.835 3.162
    Unusual Expense (Income)
    Operating Income -5.389 -6.131 34.21 -4.538 -4.938
    Interest Income (Expense), Net Non-Operating 0 0 0 0 -0.004
    Other, Net 0.428 0.34 0.046 0.007 0.015
    Net Income Before Taxes -4.961 -5.791 34.256 -4.531 -4.927
    Net Income After Taxes -4.961 -5.791 33.941 -4.531 -4.927
    Net Income Before Extra. Items -4.961 -5.791 33.941 -4.531 -4.927
    Net Income -4.961 -5.791 33.941 -4.531 -4.927
    Income Available to Common Excl. Extra. Items -4.961 -5.791 33.941 -4.531 -4.927
    Income Available to Common Incl. Extra. Items -4.961 -5.791 33.941 -4.531 -4.927
    Diluted Net Income -4.961 -5.791 33.941 -4.531 -4.927
    Diluted Weighted Average Shares 20.9598 20.9396 23.4819 20.4982 19.5026
    Diluted EPS Excluding Extraordinary Items -0.23669 -0.27656 1.44541 -0.22104 -0.25263
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.23669 -0.27656 1.44541 -0.22104 -0.25263
    Revenue 3.674 1.749 39.85 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 48.986 26.067 17.668 12.664 15.8997
    Cash and Short Term Investments 42.683 24.753 16.399 12.2168 14.7258
    Cash & Equivalents 42.634 24.534 16.399 9.21955 8.7443
    Short Term Investments 0.049 0.219 2.99722 5.98152
    Prepaid Expenses 1.373 1.314 1.269 0.44721 0.55543
    Other Current Assets, Total 0.08 0 0.61842
    Total Assets 48.992 26.077 17.682 12.9688 16.0429
    Property/Plant/Equipment, Total - Net 0.006 0.01 0.014 0.27912 0.11247
    Property/Plant/Equipment, Total - Gross 0.025 0.025 0.025 0.55084 0.82159
    Accumulated Depreciation, Total -0.019 -0.015 -0.011 -0.27172 -0.70912
    Long Term Investments 0.02568 0.03079
    Total Current Liabilities 2.753 3.855 3.185 2.9055 3.15255
    Accounts Payable 1.069 1.584 1.214 0.48829 0.54752
    Accrued Expenses 1.369 1.733 1.971 0.91721 2.60503
    Notes Payable/Short Term Debt 0 0.538 0 0 0
    Total Liabilities 2.753 3.855 31.149 3.01082 5.48004
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0 0 27.964 0.10532 2.32749
    Total Equity 46.239 22.222 -13.467 9.95795 10.5629
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.002 0.002 0.001 0.0004 0.00375
    Additional Paid-In Capital 117.717 111.588 19.207 173.278 165.264
    Retained Earnings (Accumulated Deficit) -71.48 -89.368 -32.675 -163.323 -154.687
    Other Equity, Total 0.00208 -0.01784
    Total Liabilities & Shareholders’ Equity 48.992 26.077 17.682 12.9688 16.0429
    Total Common Shares Outstanding 20.8613 18.8458 10.8825 1.00479 0.78179
    Other Current Liabilities, Total 0.315 0 1.5
    Total Receivables, Net 4.85
    Accounts Receivable - Trade, Net 4.85
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 45.399 48.986 14.561 17.891 20.476
    Cash and Short Term Investments 39.01 42.683 13.956 17.151 19.381
    Cash & Equivalents 38.988 42.634 13.855 17.025 19.246
    Prepaid Expenses 1.01 1.373 0.544 0.709 1.095
    Other Current Assets, Total 0.078 0.08 0.061 0.031
    Total Assets 45.404 48.992 14.568 17.899 20.485
    Property/Plant/Equipment, Total - Net 0.005 0.006 0.007 0.008 0.009
    Property/Plant/Equipment, Total - Gross 0.025 0.025 0.025 0.025 0.025
    Accumulated Depreciation, Total -0.02 -0.019 -0.018 -0.017 -0.016
    Total Current Liabilities 4.154 2.753 2.691 3.304 3.213
    Accounts Payable 2.221 1.069 1.468 1.886 1.579
    Accrued Expenses 1.618 1.369 1.223 1.418 1.419
    Notes Payable/Short Term Debt 0 0 0 0 0.215
    Total Liabilities 4.154 2.753 2.691 3.304 3.213
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0 0 0 0 0
    Total Equity 41.25 46.239 11.877 14.595 17.272
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.002 0.002 0.002 0.002 0.002
    Additional Paid-In Capital 118.519 117.717 117.296 115.483 113.233
    Retained Earnings (Accumulated Deficit) -77.271 -71.48 -105.421 -100.89 -95.963
    Total Liabilities & Shareholders’ Equity 45.404 48.992 14.568 17.899 20.485
    Total Common Shares Outstanding 20.9478 20.8613 20.8015 20.0996 19.2136
    Total Receivables, Net 5.301 4.85
    Accounts Receivable - Trade, Net 5.301 4.85
    Short Term Investments 0.022 0.049 0.101 0.126 0.135
    Other Current Liabilities, Total 0.315 0.315
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 17.888 -56.693 -24.62 -8.63543 -14.3685
    Cash From Operating Activities 14.314 -19.37 -6.797 -10.2771 -18.8386
    Cash From Operating Activities 0.004 0.004 0.008 0.04099 0.04821
    Non-Cash Items 1.977 37.138 16.669 -1.90774 -4.66764
    Changes in Working Capital -5.555 0.181 1.146 0.22505 0.14932
    Cash From Investing Activities 0 -0.1 0.539 3.09855 11.911
    Capital Expenditures 0 -0.01938 -0.03922
    Other Investing Cash Flow Items, Total 0 -0.1 0.539 3.11793 11.9502
    Cash From Financing Activities 3.786 27.605 21.12 7.65383 6.77279
    Issuance (Retirement) of Stock, Net 4.455 28.578 -0.448 7.65383 6.87279
    Net Change in Cash 18.1 8.135 14.862 0.47525 -0.15485
    Financing Cash Flow Items -0.131 -1.619 19.371 0 -0.1
    Cash Taxes Paid 0 0 0
    Cash Interest Paid 0.009 0.002 0
    Issuance (Retirement) of Debt, Net -0.538 0.646 2.197
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -5.791 17.888 -16.053 -11.522 -6.595
    Cash From Operating Activities -3.646 14.314 -14.477 -9.979 -6.17
    Cash From Operating Activities 0.001 0.004 0.003 0.002 0.001
    Non-Cash Items 0.831 1.977 1.501 0.983 0.529
    Cash Taxes Paid 0 0 0 0 0
    Cash Interest Paid 0 0.009 0.009 0.009 0.005
    Changes in Working Capital 1.313 -5.555 0.072 0.558 -0.105
    Cash From Investing Activities 0 0 0 0 0
    Other Investing Cash Flow Items, Total 0 0 0 0 0
    Cash From Financing Activities 0 3.786 3.798 2.47 0.882
    Issuance (Retirement) of Stock, Net 0 4.455 4.455 3.093 1.235
    Issuance (Retirement) of Debt, Net 0 -0.538 -0.538 -0.538 -0.323
    Net Change in Cash -3.646 18.1 -10.679 -7.509 -5.288
    Financing Cash Flow Items 0 -0.131 -0.119 -0.085 -0.03

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Ocuphire Pharma, Inc. Company profile

    Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
    Industry: Pharmaceuticals (NEC)

    37000 Grand River Ave.
    Suite 120
    FARMINGTON HILLS
    MICHIGAN 48335
    US

    Income Statement

    • Annual
    • Quarterly

    News

    How to Trade The Triple Top

    Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

    14:13, 27 September 2023
    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    People also watch

    BTC/USD

    27,089.95 Price
    +0.520% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    XRP/USD

    0.52 Price
    -3.510% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    US100

    14,744.20 Price
    +0.120% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    ETH/USD

    1,677.13 Price
    +0.400% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading